This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (38)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

A Comparative Study

François Paye, MD; Pascal Jagot, MD; Valérie Vilgrain, MD; Olivier Farges, MD, PhD; Dominique Borie, MD; Jacques Belghiti, MD, PhD

Arch Surg. 1998;133:767-772.

Objective  To assess the efficacy and adverse effects of preoperative transcatheter chemoembolization (CE) on surgical resection, postoperative outcome, and recurrence of hepatocellular carcinoma.

Design  A before-after trial comparing a group of patients undergoing liver resection after CE (CE group) with a group of patients undergoing liver resection without prior CE (control group), matched for tumor size and underlying liver disease.

Setting  A tertiary care university hospital in a metropolitan area.

Patients  Twenty-four patients in each group, treated between 1986 and 1992.

Interventions  A mean of 1.6±0.2 preoperative CE procedures were performed per patient in the CE group. Tumorectomies, segmentectomies, and major liver resections were performed with a comparable frequency in each group.

Results  Overall, CE was not associated with a significant reduction of tumor size (7.8±1 cm prior to CE vs 7.1±1 cm after CE) or -fetoprotein levels (2560±2091 µg/L prior to CE vs 1788±1270 µg/L after the last CE). Chemoembolization promoted tumor necrosis but did not influence tumor encapsulation, invasion of the capsule, venous permeation, presence of daughter nodules, or surgical margins. Liver resection was rendered more difficult by preoperative CE as a result of pediculitis and gallbladder lesions in 37% of patients, but the postoperative course was not altered. Disease-free survival (33±12% vs 32±12% at 3 years) and overall survival were comparable.

Conclusions  Convincing evidence is lacking to support systematic preoperative CE in patients with initially resectable hepatocellular carcinoma. Further studies should aim to identify the subgroup of patients who may benefit from this neoadjuvant treatment.

From the Departments of Digestive Surgery (Drs Paye, Jagot, Farges, Borie, and Belghiti) and Radiology (Dr Vilgrain), Hôpital Beaujon, University Paris VII, Clichy, France.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Percutaneous Radiofrequency Ablation of Hepatic Tumors: Postablation Syndrome
Dodd et al.
Am. J. Roentgenol. 2005;185:51-57.
ABSTRACT | FULL TEXT